250 Chapter 10 In summary, in this randomized trial we found no indication that performing ULDCT instead of CXR in febrile or hypothermic patients clinically suspected of CAP at the ED affects antibiotic treatment or patient outcomes. In afebrile patients however, ULDCT might have a higher sensitivity to diagnose CAP compared to CXR. Funding/support This work was supported by an innovation grant of the Amsterdam University Medical Centers (Amsterdam UMC), location Academic Medical Center (AMC), University of Amsterdam and a Health Care Efficiency Program grant of the Netherlands Organization for Health Research and Development (ZonMW: 843001806). Amsterdam UMC and ZonMW had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Acknowledgements We thank the patients and patient representatives who were involved in the OPTIMACT study. We kindly acknowledge all members of the OPTIMACT study group: Jouke Annema, Ludo F.M. Beenen, Dominique Bekebrede-Kaufman, Joost W. van den Berg, Sophie J. Bernelot Moens, Shandra Bipat, Bart G. Boerrigter, Marije M.K. Bomers, Marjolein A.W. van den Boogert, Merel L.J. Bouwman, Paul Bresser, Annemieke K. van den Broek, Brenda Elzer, Jos Donkers, Elvin Eryigit, Betty Frankemölle, Nina-Suzanne Groeneveld, Maarten Groenink, Emo E. van Halsema, Naomi M. Haverkamp Begemann, Suzanne M.R. Höchheimer, David ten Hoff, Frits Holleman, Erwin Hoolwerf, Dorine Hulzebosch, Mitran Keijzers, Saskia Kolkman, Jos A.J. Kooter, Daniel A. Korevaar, Ivo van der Lee, Nick H.J. Lobe, Peter A. Leenhouts, Ramon B. van Loon, Paul Luijendijk, Melanie A. Monraats, Bregje Mol, Jan Luitse, Lilian J. Meijboom, Carmen M. Melaan, Saskia Middeldorp, Alexander Montauban van Swijndregt, Wouter de Monyé, Jacqueline Otker, Anna Pijning, Tom van der Poll, Adrienne van Randen, Tom D.Y. Reijnders, Milan L. Ridderikhof, Johannes A. Romijn, Jorien M. van Rooijen, Maeke J. Scheerder, Antoinet J.N. Schoonderwoerd, Laura J. Schijf, Frank F. Smithuis, Ralf W. Sprengers, Robin Soetekouw, Geert J. Streekstra, Elizabeth M. Taal, Milou M. Tjong Joe Wai, Merve S. Tulek, Glenn de Vries, Daphne D.L. van der Velden, Saskia Veldkamp, Loek Verdegaal, Maaike J.A. Vogel, Lonneke A. van Vught, Mart Vuurboom, Guus A. Westerhof, Pieta C. Wijsman, Michiel M. Winter, Rosa D. Wouda, Ibtisam Yahya. Author’s contributions JS, JMP, IAHvdB, MMNPK, PMMB, MGWD, and TSRvE were involved in design, planning and execution, and data interpretation of the main trial. For further details, please see the main paper of the OPTIMACT trial [8]. JMP was the principal investigator of this preplanned subgroup analysis of the OPTIMACT trial. TSRvE performed the analyses. TSRvE and JMP drafted the manuscript. All authors were involved in data interpretation, critically revised the manuscript, approved the final version of the manuscript, and agree to be accountable for all aspects of this trial. The corresponding
RkJQdWJsaXNoZXIy MTk4NDMw